The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Open accessAbstract
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a first-in-class fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) inhibitor that suppresses PD-1 activity through selectively targeting and blocking the interaction between ligands (PD-L1 and PD-L2) and PD-1 receptor [35].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [35]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,000
Hercun, J., Vincent, C., Bilodeau, M., & Lapierre, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907591 · Cited by 61
Santarpía, M., González‐Cao, M., Viteri, S., Karachaliou, N., Altavilla, G., & Rosell, R. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.12.04 · Cited by 61
Addressing the challenges of applying precision oncology
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 65
Ott, M., Tomaszowski, K.-H., Marisetty, A., Kong, L.-Y., Wei, J., Duna, M., Blumberg, K., Ji, X., Jacob, C., Fuller, G. N., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134386 · Cited by 61
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment
Corrales, L., Scilla, K. A., Caglevic, C., Miller, K., Oliveira, J., & Rolfo, C. D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_3 · Cited by 65
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 60
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 61
Immune checkpoint inhibitors in older adults
Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0534-9 · Cited by 59
Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
Vennepureddy, A., Thumallapally, N., Nehru, V. M., Atallah, J. P., & Terjanian, T. O. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2424w · Cited by 61
Owonikoko, T. K., Kumar, M., Yang, S., Kamphorst, A. O., Pillai, R. N., Akondy, R. S., Nautiyal, V., Chatwal, M. S., Book, W., Sahu, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1918-2 · Cited by 61
Self-citationIntratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer
Nakamura, S., Hayashi, K., Imaoka, Y., Kitamura, Y., Akazawa, Y., Tabata, K., de Groen, R. A. L., Tsuchiya, T., Yamasaki, N., Nagayasu, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186192 · Cited by 60
Khunger, M., Jain, P., Rakshit, S., Pasupuleti, V., Hernández, A. V., Stevenson, J. P., Pennell, N. A., & Velcheti, V. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.01.002 · Cited by 59
Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome
Mirza, S., Hill, E., Ludlow, S. P., & Nanjappa, S. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000326 · Cited by 58
The inflammatory microenvironment in brain metastases: potential treatment target?
Berghoff, A. S., & Preusser, M. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.06.03 · Cited by 59
Seo, H., Kim, B. S., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0708 · Cited by 59
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58
Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
Garon, E. B. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.019 · Cited by 57
Immunotherapy in Non–Small Cell Lung Cancer Treatment
Carter, B. W., Halpenny, D. F., Ginsberg, M. S., Papadimitrakopoulou, V. A., & de Groot, P. M. (2017) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000291 · Cited by 57
Abdallah, S. M.-B., & Wong, A. N. M. (2018) · Current Oncology · doi:10.3747/co.25.3733 · Cited by 57
Li, Y. D., Lamano, J. B., Lamano, J. B., Quaggin-Smith, J. A., Veliceasa, D., Kaur, G., Biyashev, D., Unruh, D. J., & Bloch, O. G. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02384-y · Cited by 57
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
Williams, G. S., Mistry, B., Guillard, S., Ulrichsen, J. C., Sandercock, A. M., Wang, J., González-Muñoz, A., Parmentier, J. M., Black, C. M., Soden, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11943 · Cited by 56
Potential role of immunotherapy in advanced non-small-cell lung cancer
de Mello, R. A., Veloso, A. F. D. H., Catarina, P. E. M., Nadine, S., & Αντωνίου, Γ. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s90459 · Cited by 56
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 57
Xia, F., Xiu, B., Yang, Z.-Z., Qiu, W., Zhang, L., Zhang, S., Wu, Y., Zhu, X., Chen, X., Xie, S., et al. (2017) · Medicine · doi:10.1097/md.0000000000006398 · Cited by 58
Granata, V., Fusco, R., Costa, M., Picone, C., Cozzi, D., Moroni, C., Casella, G. V. L., Montanino, A., Monti, R., Mazzoni, F., et al. (2021) · Cancers · doi:10.3390/cancers13163992 · Cited by 55
Understanding the checkpoint blockade in lung cancer immunotherapy
Bello, M. G. D., Alama, A., Coco, S., Vanni, I., & Grossi, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.016 · Cited by 55
Kobayashi, K., Nakachi, I., Naoki, K., Satomi, R., Nakamura, M., Inoue, T., Tateno, H., Sakamaki, F., Sayama, K., Terashima, T., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.01.001 · Cited by 56
Immune checkpoints and cancer development: Therapeutic implications and future directions
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 55
Anti–PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Reungwetwattana, T., & Adjei, A. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.008 · Cited by 55
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
Wang, J., Li, M., Zhang, Y., Teng, F., Han, A., Kong, L., & Zhu, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94993 · Cited by 54
Tsai, Y.-T., Schlom, J., & Donahue, R. N. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02969-1 · Cited by 56
Fu, J., Wang, F., Dong, L., Zhang, J., Deng, C.-L., Wang, X., Xie, X.-Y., Zhang, J., Deng, R., Zhang, L., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.161 · Cited by 54
Wan, N., Zhang, T., Hua, S., Lu, Z., Ji, B., Li, L., Lu, L., Huang, W., Jiang, J., & Li, J. (2020) · Cancer Medicine · doi:10.1002/cam4.2793 · Cited by 54
Maghrouni, A., Givari, M., Jalili‐Nik, M., Mollazadeh, H., Bibak, B., Sadeghi, M. M., Afshari, A. R., Johnston, T. P., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107403 · Cited by 56
Ma, R., Rei, M., Woodhouse, I. B., Ferris, K., Kirschner, S. A., Chandran, A., Gileadi, U., Chen, J., Pinho, M. P., Ariosa-Morejon, Y., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac107 · Cited by 55
Garassino, M. C., Cho, B. C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Léna, H., Jaime, J. C., Gray, J. E., Powderly, J. D., CHOUAID, C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.032 · Cited by 53
Self-citationMunhoz, R. R., Marta, G. N., de Camargo, V. P., Queiroz, M. M., Cury‐Martins, J., Ricci, H., de Mattos, M. R., de Menezes, T. A. F., Machado, G. U., Bertolli, E., et al. (2022) · Cancer · doi:10.1002/cncr.34463 · Cited by 56
Kazandjian, D. G., Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S. W., Libeg, M., Kluetz, P. G., Sridhara, R., Keegan, P., & Pazdur, R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3934 · Cited by 53
Ohue, Y., Kurose, K., Nozawa, R., Isobe, M., Nishio, Y., Tanaka, T., Doki, Y., Hori, T., Fukuoka, J., Oka, M., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0266 · Cited by 53
Giunchi, F., Degiovanni, A., Daddi, N., Trisolini, R., Dell’Amore, A., Agostinelli, C., Ardizzoni, A., & Fiorentino, M. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000458 · Cited by 53
Srivastava, R., Khan, A. A., Chilukuri, S., Syed, S. A., Tran, T. T., Furness, J. N., Bahraoui, E., & BenMohamed, L. (2017) · Journal of Virology · doi:10.1128/jvi.00278-17 · Cited by 53
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Molecular and clinical characterization of Galectin‐9 in glioma through 1,027 samples
Yuan, F., Ming, H., Wang, Y., Yang, Y., Li, Y., Li, T., Ma, H., Tong, L., Zhang, L., Liu, P., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29309 · Cited by 53
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Gergely, T. G., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., Rassaf, T., Ferdinandy, P., & Varga, Z. V. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00986-9 · Cited by 57
Cancer immunotherapy via nucleic acid aptamers
Khedri, M., Rafatpanah, H., Abnous, K., Ramezani, P., & Ramezani, M. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.10.013 · Cited by 52
Iwamoto, N., Shimada, T., Terakado, H., & Hamada, A. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.038 · Cited by 52
Gelsomino, F., Vitale, G., & Ardizzoni, A. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0484-6 · Cited by 52
New advances in immunotherapy for non-small cell lung cancer.
Qin, H., Wang, F., Liu, H., Zeng, Z., Wang, S., Pan, X. H., & Gao, H. (2018) · Europe PMC (PubMed Central) · Cited by 52
Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
(2018) · In Vivo · doi:10.21873/invivo.11166 · Cited by 51
Tanaka, K., Miyata, H., Sugimura, K., Kanemura, T., Hamada‐Uematsu, M., Mizote, Y., Yamasaki, M., Wada, H., Nakajima, K., Takiguchi, S., et al. (2016) · Cancer Science · doi:10.1111/cas.12938 · Cited by 51
Dammeijer, F. F., Lievense, L. A., Veerman, G., Hoogsteden, H. C., Hegmans, J. P., Arends, L. R., & Aerts, J. G. J. V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.3955 · Cited by 51
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer
Zhou, G., Xiong, Y., Chen, S., Xia, F., Li, Q., & Hu, J. (2016) · Medicine · doi:10.1097/md.0000000000004611 · Cited by 51
Impact of curative radiotherapy on the immune status of patients with localized prostate cancer
Eckert, F., Schaedle, P., Zips, D., Schmid-Horch, B. D., Rammensee, H., Gani, C., & Gouttefangeas, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1496881 · Cited by 54
Fu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
de Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 51
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
Mick, R., & Chen, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0260 · Cited by 50
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma
Griffin, L. L., Cove-Smith, L., Alachkar, H., Radford, J. A., Brooke, R. C. C., & Linton, K. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.09.028 · Cited by 50
Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 49
Targeted Therapy for Cancer in the Genomic Era
Afghahi, A., & Sledge, G. W. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000135 · Cited by 49
Targeting immune checkpoints in malignant glioma
Zhang, X., Zhu, S., Li, T., Liu, Y., Chen, W., & Chen, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12702 · Cited by 52
Tie, Y., Ma, X., Zhu, C., Ye, M., Shen, K., Wei, X., Chen, Y., & Zheng, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.30501 · Cited by 50
Tumor-Infiltrating Lymphocyte Therapy and Neoantigens
Robbins, P. F. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000267 · Cited by 50
Kim, H., Griffith, T. S., & Panyam, J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254953 · Cited by 49
Juliá, E. P., Mandó, P., Rizzo, M., Cueto, G. R., Tsou, F., Luca, R., Pupareli, C. S., Bravo, A., Astorino, W., Mordoh, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02391-z · Cited by 50
Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708195 · Cited by 49
PD-L1 as a biomarker in NSCLC: challenges and future directions
Mathew, M., Safyan, R. A., & Shu, C. A. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.04 · Cited by 50
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer
Pabani, A., & Butts, C. A. (2018) · Current Oncology · doi:10.3747/co.25.3750 · Cited by 48
Sengal, A. G., Velazquez, J., Hahne, M., Burke, T. M., Abhyankar, H. A., Reyes, R., Olea, W., Scull, B., Eckstein, O. S., Bigenwald, C., et al. (2020) · Blood · doi:10.1182/blood.2020005867 · Cited by 48
Zhang, H., Bi, Y., Wei, Y., Liu, J., Kuerban, K., & Ye, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0825 · Cited by 48
Tumor mutational burden on cytological samples: A pilot study
Pepe, F., Pisapia, P., Gristina, V., Rocco, D., Micheli, M., Micheli, P., Iaccarino, A., Tufano, R., Gragnano, G., Russo, G., et al. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22400 · Cited by 47
Emerging molecular classifications and therapeutic implications for gastric cancer
Chen, T., Xu, X., & Zhou, P. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0111-5 · Cited by 47
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
Chen, Y. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2016.08.005 · Cited by 47
Biomarkers and Immunotherapeutic Targets in Glioblastoma
Hung, A. L., Garzón-Muvdi, T., & Lim, M. K. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.03.011 · Cited by 49
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model
Dai, B., Qi, N., Li, J., & Zhang, G. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.064 · Cited by 47
Kim, K. H., Choi, K. U., Kim, A., Lee, S. J., Lee, J. H., Suh, D. S., Kwon, B. S., & Hwang, C. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0526-0 · Cited by 47
Pham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.009 · Cited by 46
Remón, J., Chaput, N., & Planchard, D. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000263 · Cited by 46
Self-citationPembrolizumab-induced pneumonitis
Leroy, V., Templier, C., Faivre, J., Scherpereel, A., Fournier, C., Mortier, L., & Wémeau-Stervinou, L. (2017) · ERJ Open Research · doi:10.1183/23120541.00081-2016 · Cited by 46
Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma
Chen, Y., Liu, F., Hsu, C.-H., & Chian, C. (2017) · Medicine · doi:10.1097/md.0000000000007350 · Cited by 46
Mohamad, O., de Leon, A. D., Schroeder, S. R., Leiker, A. J., Christie, A. L., Zhang-Velten, E. R., Trivedi, L. U., Khan, S. A., Desai, N. B., Laine, A. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440168 · Cited by 46
PD-L1 expression in malignant salivary gland tumors
Harada, K., Ferdous, T., & Ueyama, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4069-3 · Cited by 46
Richard, C., Fumet, J.-D., Chevrier, S., Dérangère, V., Ledys, F., Lagrange, A., Favier, L., Coudert, B. P., Arnould, L., Truntzer, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1940 · Cited by 49
Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y. Q., Rosin‐Arbesfeld, R., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01756-y · Cited by 46
Wauters, E., Janssens, W., Vansteenkiste, J., Decaluwé, H., Heulens, N., Thienpont, B., Zhao, H., Smeets, D., Sagaert, X., Coolen, J., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207288 · Cited by 45
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0589-9 · Cited by 45
Tumor-Infiltrating Lymphocyte Therapy
Radvanyi, L. G. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000162 · Cited by 45
Scarpace, S. L. (2015) · Drugs in Context · doi:10.7573/dic.212289 · Cited by 45
Wang, Y., Lin, J., Cui, J., Han, T., Jiao, F., Zhuo, M., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14069 · Cited by 45
Wang, M., Ma, X., Guo, L., & Xia, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s146286 · Cited by 45
Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance
Wang, X., Zhang, J., Cao, G., Hua, J., Shan, G., & Lin, W. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02432-z · Cited by 46
PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
Hutarew, G. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0292-2 · Cited by 44
A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment
Chubachi, S., Yasuda, H., Irie, H., Fukunaga, K., Naoki, K., Soejima, K., & Betsuyaku, T. (2016) · Case Reports in Oncological Medicine · doi:10.1155/2016/1075641 · Cited by 44
Illouz, F., Briet, C., Cloix, L., Corre, Y. L., Baize, N., Urban, T., Martin, L., & Rodien, P. (2017) · Cancer Medicine · doi:10.1002/cam4.1145 · Cited by 44
Histology of Nivolumab-Induced Thyroiditis
Neppl, C., Kaderli, R. M., Trepp, R., Schmitt, A. M., Berger, M. D., Wehrli, M., Seiler, C. A., & Langer, R. (2018) · Thyroid · doi:10.1089/thy.2018.0418 · Cited by 44
Improving Cancer Vaccine Efficiency by Nanomedicine
Cai, J., Wang, H., Wang, D., & Li, Y. (2019) · Advanced Biosystems · doi:10.1002/adbi.201800287 · Cited by 44
Anker, M. S., Hadzibegovic, S., Lena, A., Belenkov, Y. N., Bergler-Klein, J. K., de Boer, R. A., Farmakis, D. T., von Haehling, S., Iakobishvili, Z., Maack, C., et al. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12551 · Cited by 46
Thuillier, P., Joly, C., Alavi, Z., Crouzeix, G., Descourt, R., Quéré, G., Kerlan, V., & Roudaut, N. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02802-6 · Cited by 44
Zhang, F., Ferrero, M., Dong, N., D’Auria, G., Reyes‐Prieto, M., Herreros‐Pomares, A., Fariñas, S. C., Duréndez-Saéz, E., Aparisi, F., Blasco, A., et al. (2021) · Cancers · doi:10.3390/cancers13112514 · Cited by 45
Metadata
- Authors
- Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Gustave Roussy (FR)
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Azienda Ospedaliera S.Maria (IT)
- Hôpital Civil, Strasbourg (FR)
- The Ohio State University Wexner Medical Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Mount Sinai Beth Israel (US)
- Lehigh Valley Hospital (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- University Hospital Cologne (DE)
- Hospices Civils de Lyon (FR)
- Ospedale di Livorno (IT)
- University Hospitals of Cleveland (US)
- Providence Portland Medical Center (US)
- German Center for Lung Research (DE)
- Princeton University (US)
- Emory University (US)
- Corresponding author
- Rizvi, Naiyer A
- ORCID
- Rizvi, Naiyer A
- Mazières, Julien
- Planchard, David
- Stinchcombe, Thomas E
- Dy, Grace K
- Antonia, Scott J
- Horn, Leora
- Mennecier, Bertrand
- Otterson, Gregory A
- Campos, Luis T
- Gandara, David R
- Levy, Benjamin P
- Nair, Suresh G
- Zalcman, Gérard
- Wolf, Jürgen
- Cappuzzo, Federico
- Chouaid, Christos
- Dowlati, Afshin
- Sanborn, Rachel
- Huber, Rudolf M
- Ramalingam, Suresh S
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 257-265
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5726228
- OpenAlex
- W2106511606
- Cited by
- 1,415
- References
- 36
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
- FWCI
- 108.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
- MeSH terms
- Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
